Literature DB >> 1334975

Interleukin 1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide.

J A Corbett1, J L Wang, M A Sweetland, J R Lancaster, M L McDaniel.   

Abstract

Nitric oxide has recently been implicated as the effector molecule that mediates IL-1 beta-induced inhibition of glucose-stimulated insulin secretion and beta-cell specific destruction. The pancreatic islet represents a heterogeneous cell population containing both endocrine cells (beta-[insulin], alpha-]glucagon], gamma[somatostatin], and PP-[polypeptide] secreting cells) and non-endocrine cells (fibroblast, macrophage, endothelial, and dendritic cells). The purpose of this investigation was to determine if the beta-cell, which is selectively destroyed during insulin-dependent diabetes mellitus, is both a source of IL-1 beta-induced nitric oxide production and also a site of action of this free radical. Pretreatment of beta-cells, purified by FACS with IL-1 beta results in a 40% inhibition of glucose-stimulated insulin secretion that is prevented by the nitric oxide synthase inhibitor, NG-monomethyl-L-arginine (NMMA). IL-1 beta induces the formation of nitric oxide by purified beta-cells as evidenced by the accumulation of cGMP, which is blocked by NMMA. IL-1 beta also induces the accumulation of cGMP by the insulinoma cell line Rin-m5F, and both NMMA as well as the protein synthesis inhibitor cycloheximide prevent this cGMP accumulation. Iron-sulfur proteins appear to be intracellular targets of nitric oxide. IL-1 beta induces the formation of an iron-dinitrosyl complex by Rin-m5F cells indicating that nitric oxide mediates the destruction of iron-sulfur clusters of iron containing enzymes. This is further demonstrated by IL-1 beta-induced inhibition of glucose oxidation by purified beta-cells, mitochondrial aconitase activity of dispersed islet cells, and mitochondrial aconitase activity of Rin-m5F cells, all of which are prevented by NMMA. IL-1 beta does not appear to affect FACS-purified alpha-cell metabolic activity or intracellular cGMP levels, suggesting that IL-1 beta does not exert any effect on alpha-cells. These results demonstrate that the islet beta-cell is a source of IL-1 beta-induced nitric oxide production, and that beta-cell mitochondrial iron-sulfur containing enzymes are one site of action of nitric oxide.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1334975      PMCID: PMC443394          DOI: 10.1172/JCI116129

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Interleukin 1 inhibits insulin secretion from isolated rat pancreatic islets by a process that requires gene transcription and mRNA translation.

Authors:  J H Hughes; J R Colca; R A Easom; J Turk; M L McDaniel
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

2.  Confocal microscopic analysis of the nonendocrine cellular component of isolated adult rat islets of Langerhans.

Authors:  C M Setum; J R Serie; O D Hegre
Journal:  Transplantation       Date:  1991-05       Impact factor: 4.939

3.  Interleukin-1 induces rapid and transient expression of the c-fos proto-oncogene in isolated pancreatic islets and in purified beta-cells.

Authors:  J H Hughes; M A Watson; R A Easom; J Turk; M L McDaniel
Journal:  FEBS Lett       Date:  1990-06-18       Impact factor: 4.124

4.  Secretagogue-induced oscillations of cytoplasmic Ca2+ in single beta and alpha-cells obtained from pancreatic islets by fluorescence-activated cell sorting.

Authors:  J L Wang; M L McDaniel
Journal:  Biochem Biophys Res Commun       Date:  1990-01-30       Impact factor: 3.575

Review 5.  The HLA-IDDM association: implications for etiology and pathogenesis of IDDM.

Authors:  J Nerup; T Mandrup-Poulsen; J Mølvig
Journal:  Diabetes Metab Rev       Date:  1987-07

6.  L-citrulline production from L-arginine by macrophage nitric oxide synthase. The ureido oxygen derives from dioxygen.

Authors:  N S Kwon; C F Nathan; C Gilker; O W Griffith; D E Matthews; D J Stuehr
Journal:  J Biol Chem       Date:  1990-08-15       Impact factor: 5.157

7.  EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages.

Authors:  J R Lancaster; J B Hibbs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

8.  Heat shock protein induction in rat pancreatic islets by recombinant human interleukin 1 beta.

Authors:  S Helqvist; B S Polla; J Johannesen; J Nerup
Journal:  Diabetologia       Date:  1991-03       Impact factor: 10.122

9.  Interleukin-1 beta-induced formation of EPR-detectable iron-nitrosyl complexes in islets of Langerhans. Role of nitric oxide in interleukin-1 beta-induced inhibition of insulin secretion.

Authors:  J A Corbett; J R Lancaster; M A Sweetland; M L McDaniel
Journal:  J Biol Chem       Date:  1991-11-15       Impact factor: 5.157

10.  An interleukin-1 receptor antagonist protein protects insulin-producing beta cells against suppressive effects of interleukin-1 beta.

Authors:  D L Eizirik; D E Tracey; K Bendtzen; S Sandler
Journal:  Diabetologia       Date:  1991-06       Impact factor: 10.122

View more
  79 in total

1.  FoxO1 and SIRT1 regulate beta-cell responses to nitric oxide.

Authors:  Katherine J Hughes; Gordon P Meares; Polly A Hansen; John A Corbett
Journal:  J Biol Chem       Date:  2011-01-01       Impact factor: 5.157

2.  Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).

Authors:  Rhonda D Wideman; Irene L Y Yu; Travis D Webber; C Bruce Verchere; James D Johnson; Anthony T Cheung; Timothy J Kieffer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

3.  Activation of c-Jun NH2-terminal kinase (JNK) pathway during islet transplantation and prevention of islet graft loss by intraportal injection of JNK inhibitor.

Authors:  H Noguchi; Y Nakai; M Ueda; Y Masui; S Futaki; N Kobayashi; S Hayashi; S Matsumoto
Journal:  Diabetologia       Date:  2007-01-16       Impact factor: 10.122

4.  Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumour necrosis factor-alpha in patients with recent-onset type 1 diabetes.

Authors:  S Uno; A Imagawa; K Okita; K Sayama; M Moriwaki; H Iwahashi; K Yamagata; S Tamura; Y Matsuzawa; T Hanafusa; J Miyagawa; I Shimomura
Journal:  Diabetologia       Date:  2007-01-13       Impact factor: 10.122

5.  Differential responses of pancreatic β-cells to ROS and RNS.

Authors:  Gordon P Meares; Dominique Fontanilla; Katarzyna A Broniowska; Teresa Andreone; Jack R Lancaster; John A Corbett
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-01-15       Impact factor: 4.310

6.  IL-1 mediates amyloid-associated islet dysfunction and inflammation in human islet amyloid polypeptide transgenic mice.

Authors:  Clara Y Westwell-Roper; Cyrus A Chehroudi; Heather C Denroche; Jaques A Courtade; Jan A Ehses; C Bruce Verchere
Journal:  Diabetologia       Date:  2014-12-10       Impact factor: 10.122

7.  Pathogenicity of T helper 2 T-cell clones from T-cell receptor transgenic non-obese diabetic mice is determined by tumour necrosis factor-alpha.

Authors:  Jing He; Kathryn Haskins
Journal:  Immunology       Date:  2007-11-05       Impact factor: 7.397

8.  Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes.

Authors:  Hideaki Kaneto; Taka-Aki Matsuoka; Yoshihisa Nakatani; Dan Kawamori; Takeshi Miyatsuka; Munehide Matsuhisa; Yoshimitsu Yamasaki
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

9.  Translational control of inducible nitric oxide synthase by p38 MAPK in islet β-cells.

Authors:  Yurika Nishiki; Adeola Adewola; Masayuki Hatanaka; Andrew T Templin; Bernhard Maier; Raghavendra G Mirmira
Journal:  Mol Endocrinol       Date:  2012-12-18

10.  Myricetin protects against cytokine-induced cell death in RIN-m5f β cells.

Authors:  Ye Ding; Zhao-Feng Zhang; Xiao-Qian Dai; Yong Li
Journal:  J Med Food       Date:  2012-06-25       Impact factor: 2.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.